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Turning Wallboard
Outto Pasture
Building a 2,000-square-foot house leaves
about a ton ofgypsum wallboard waste from
end cuts, window and door cutouts, and bro-
ken boards. In the United States, three million
tons ofgypsum wallboard waste is dumped in
landfills each year. In addition to depleting
space, microbial action can decompose gyp-
sum to malodorous hydrogen sulfide gas,
which athigh enough exposures can cause irri-
tation ofthe mucous linings, headache, dizzi-
ness, nausea, convulsions, coma, anddeath.
A study at the University ofWisconsin at
Madison by soil scientist Richard Wolkowski,
published in theJanuary-February 2000 issue
of Communications in Soil Science and Plant
Analysis, found that clean scrap gypsum wall-
board can be crushed and applied to alfalfa as
fertilizer. Alfalfa covers over three million
acres in Wisconsin and is fed to dairy cows
and other livestock. This crop requires large
amounts of sulfur as a nutrient. Although
commercial gypsum fertilizer has existed for a
long time, says Wolkowski, crushed gypsum
wallboardwaste provides awayto reduce con-
struction waste while nourishing thesoil.
For three growing seasons, crushed wall-
board was spread on alfalfa fields at four
University ofWisconsin agricultural research
stations with different soil types and climates
at rates ranging
from 1 ton per acre
to 16 tons per acre.
Alfalfa yields were
similar to those
from fields treated
with commercial
gypsum fertilizer.
"[Crushed wall-
board] had neither
a strong positive
nor negative agro-
nomic effects on
alfalfa production,"
Building better crops. Scientists spread crushed
gypsum wallboard on alfalfa fields as a fertilizer.
Wolkowski says. He concludes that there is
thus a reasonable alternative to tossing the
waste into landfills.
Larger amounts of crushed wallboard
were no better for the alfalfa than smaller
amounts. Wolkowski explains that the largest
amounts ofcrushed wallboard raised concen-
trations of soil calcium and sulfur but low-
ered soil magnesium; the excess calcium from
the wallboard displaces magnesium from the
soil, allowing it to leach away. Alfalfa grown
on magnesium-deficient soil could therefore
become magnesium-depleted and potentially
cause tetany if fed to cows (the muscular
spasms and twitching of tetany result from
insufficient minerals such as magnesium).
Sandy soils are especially susceptible to mag-
nesium deficiency because they have little
natural magnesium and a low soil organic
matter content. The magnesium content of
alfalfa grown with crushed wallboard should
be checked, says Wolkowski.
Finding a source ofwaste wallboard poses
the greatest obstacle. Wolkowski teamed up
with a local wallboard distributor who col-
lected scraps from building sites. The materi-
al was hauled to a processing site, ground in a
hammer mill, and sieved through a 12-mil-
limeter screen. "It came out looking like
lumpyflour," says Wolkowski.
Furthermore, state laws may stifle its
application. In Wisconsin, for instance, wall-
board is classified as a solidwaste, and spread-
ing it on agricultural lands requires a permit.
Promoting the recycling of wallboard will
probably require local effort. The ideal situa-
tion, says Wolkowski, would be for a "local
fertilizer dealer who's open-minded about
waste management to team up with a wall-
board dealer." If anyone steps forward and
takes up the challenge, Wolkowski's studies
prove it can be done. -Carol Potera
New Drugs Engineered to
Fight Asthma
Environmental allergens such as those associated with dust mites and cock-
roaches can trigger asthma attacks in predisposed individuals when they
overwhelm the immunoglobulin E (IgE) cascade, a system believed to pro-
tect the body against parasitic invasion. About 5,000 people die each year
from asthma attacks, and doctors believe that all those deaths could be pre-
vented. At the American Academy of Allergy, Asthma and Immunology
annual meeting, held 3-8 March 2000 in San Diego, California, doctors
detailed how investigational bioengineered drugs target and soak up IgE
and interleukin-4 (IL-4), key modulators of the IgE cascade. The drugs may
eventually replace corticosteroids, currently the drug of choice, as preven-
tive medication.
Henry Milgrom, a senior staff physician at National Jewish Medical and
Research Center in Denver, Colorado, described progress in clinical trials
with anti-lgE, a compound developed jointly by the drug companies
Genentech, Novartis Pharma AG, and Tanox. "This is a breakthrough-anti-
lgE was designed to perform a specific function in suppressing a disease
process and itworks," Milgrom said.
Among the 268 adult patients suffering from moderate to severe
asthma who received injections of anti-lgE in the first phase of a 28-week
study, only 14.6% had asthma attacks, compared with 23.3% of the 257
patients on placebo. There were also reduced exacerbations of asthma dur-
ing the second phase of the study when steroid medication was withdrawn.
In a second study involving 334 asthmatic children, 55% of the chil-
dren receiving anti-lgE were able to discontinue all steroid medication with-
out suffering asthma attacks, compared to about 39% of patients receiving
placebo injections.
"This is an exciting approach to treatment of asthma," said Michael
Wein, chief of allergy at Indian River Memorial Hospital in Vero Beach,
Florida. "If you found something to remove IgE from the body, you
wouldn't have allergies." Milgrom said anti-lgE also has potential for peo-
ple who have food or latex allergies, atopic dermatitis, and other condi-
tions. He said a new drug application for anti-lgE will be filed with the
Food and Drug Administration this summer.
Larry Borish, an associate professor of medicine at the University of
Virginia Medical Center in Charlottesville, reported that another new drug,
IL-4R (for IL-4 receptor), is effective for 5-7 days with just one inhaled dose.
IL-4 is responsible for the respiratory inflammation associated with asthma.
Borish said the drug soaks up circulating IL-4 like a sponge.
Borish reported administering either placebo or three different
dosages of IL-4R to 15-16 patients per group in 12 weekly inhalations. The
patients were all suffering from moderate to severe asthma and had been
taking inhaled corticosteroid medication, which was stopped on the first
day of the study. The group taking the placebo showed a significant decline
in lung function, whereas this decrease in function did not occur in the
treatment group, Borish said, demonstrating the efficacy of the experimen-
tal drug. Borish said a larger study of IL-4R will be reported this summer.
In almost all chronic diseases, long-term patient noncompliance is prob-
ably the major reason why treatment eventually fails. So, says Charles
Feldman, an associate professor of pediatrics at Columbia University in New
York, the great promise of IL-4R is that if further studies prove its effective-
ness, its ease of use should improve patient compliance-a key to keeping
asthma in check. -Ed Susman
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